Genetic modifications of the BCL6 gene in lymphoma include translocations, deletions, and somatic mutations (SM) of the 5 0 noncoding region. Three single-nucleotide polymorphisms (SNPs) of the major mutation cluster region (MMC) have been reported, including two substitutions (397G/C, 502G/A) and one deletion (520DT). Clinical and biological relevance of these SNPs are unknown. Based on a case-control study, BCL6 SNPs frequencies were assessed in 97 t(14;18) follicular lymphomas (FL) and in 54 lymphomas with 3q27 rearrangement. Allele frequencies were similar in the FL and controls groups. The 397 G/C genotype was correlated to a higher-grade transformation risk (P ¼ 0.02). SM were observed in 39.1% of FL and were characterized by a clustering distribution (hot spots spanning position 420-435, 106-127, and 590-600). No correlation between genotypes or acquired mutational status and BCL6 expression was demonstrated. However, gel mobility-shift assays, using SNPs containing probes show results representative for protein/DNA complexes. This study demonstrates that the first BCL6 intron is a highly variable region as a consequence of both SNP and SM, which may contribute to biology and outcome of FL.
Introduction
The BCL6 gene, located on chromosome 3q27, encodes a transcriptional repressor acting on a broad spectrum of target genes, implicated in T and B cell maturation, cell-cycle control, apoptosis or inflammation. Its expression is crucial for the germinal center (GC) formation where its downregulation is necessary for the post-GC B cell maturation.
1 BCL6 protein is constantly expressed in follicular lymphoma (FL) 2 and expressed in diffuse large B-cell lymphoma (DLBCL) with a germinalcenter-like phenotype. 3 The first BCL6 intron is a highly conserved region and, together with the first noncoding exon, contains proposed regulatory elements at its 5 0 proximity. 4, 5 Notably, the first intronic region also displays frequent genetic alterations in lymphomas and at least three types of genetic events can occur. Translocations represent the first BCL6 gene alteration reported in lymphoma. A 3q27 translocation affecting the BCL6 gene is observed in 20-40% of DLBCL, in 15% of FL and also in a wide spectrum of B-cell lymphomas. [6] [7] [8] Rearrangements cluster in a 3.3 kb region termed major translocation cluster (MTC), which spans the first noncoding exon and the 5 0 region of the first intron of the gene. 6 Translocations do not only involve Ig genes, but other chromosomal loci as well, of which to date more than 20 non-Ig partners have been identified. 9 Secondly, deletions of variable size including a region of the MTC can occur and occasionally be associated with translocation which leads to a bi-allelic rearrangement. 4 The third type of gene alteration is constituted by somatic mutations (SM) actively targeted to the 5 0 untranslated region of the BCL6 gene, including and largely curtailed by the first intron. 10 The mutated domain, termed the major mutation cluster (MMC), 11 is a 800 bp-domain located B650 bp downstream the TATA box in the gene promoter. SM are present in B30% of normal GC B-cells, including centroblasts and centrocytes, 12, 13 40% of FL and 70% of DLBCL. [13] [14] [15] The prognosis value of BCL6 SM is a matter of debate since it has been reported that the SM status may have positive, 15, 16 negative 17 or no effect 12, 18, 19 in various lymphoproliferative disorders. In addition to acquired SM, three singlenucleotide polymorphisms (SNPs) have been reported within the MMC, and include two substitutions at position 397 (G4C) and 502 (G4A), and one deletion of T at position 520 (T4DT). 10, 20 In a study based on a North-American population, it was shown that the 397C polymorphism correlated with an increased risk to develop FL. 21 However, frequencies and clinical relevance of the variability of the MMC related to both polymorphic changes and acquired SM in an European population are currently unknown. The aim of this study was to assess the frequency of three SNPs of the MMC and to describe BCL6 SM and their clinical relevance in a large series of FL.
Patients and methods

Patients
Patients included into this retrospective study had a diagnosis of FL based on morphology and immunophenotypic analysis according to the WHO classification, available tumor DNA before any treatment, adequate staging and follow-up, and the detection of a t(14;18) translocation by conventional cytogenetic methods. DNA from lymph nodes biopsies at the time of initial diagnosis of 97 patients with FL diagnosed between 1986 and 2002 and bearing the t(14;18) translocation were studied. Staging included routine blood chemistry tests, lactate dehydrogenase (LDH) level, computed tomography (CT) of chest, abdomen and pelvis, and bone marrow biopsy. Clinical characteristics of the patient population are summarized in Table 1 . The median overall survival (OS) of the 97 patients was 109 months. The median follow-up was 69.6 months. In addition, SNP frequencies was assessed in 54 NHL patients (27 females and 27 males, median age of 63 years, range 29-86 years) harboring a 3q27 translocation, including 37 DLBCL, three nodal marginal zone lymphoma (MZL) and 14 FL. A total of 44 cases harbored a t(3;14)(q27;q32) and 10 cases a variant translocation (including five t(3;22)(q27;q11) and two t(2;3)(p12;q27)).
Controls
DNA control was obtained from peripheral blood mononuclear cells (PBMCs) of 106 unrelated healthy blood donors (50 females and 56 males; median of age of 50.5 years, range 29-87 years). FL patients and control subjects were selected from the same population living in Normandy, were of Caucasian origin, and were matched according to age and sex.
The median age of the group of 54 patients with 3q27 þ NHL was significantly higher than controls, but the two groups were similar regarding sex ratio and ethnic origin. For controls, a unique PCR product of 250 bp within the MMC and encompassing the three SNPs was amplified using 5 0 -GCGGCCGGAG CAGAG-3 0 and 5 0 -CCTCCCGGAGTTACCCAGAA-3 0 primers and directly sequenced. A total of 55 available matched DNA from PBMCs of FL patients were sequenced to assess the acquired or inherited origin of the mutation.
Genotyping and mutation analysis
Acquired SM and SNP of the MMC region (791 bp) were assessed by PCR amplification and direct sequencing as previously described. 20 Both strands were sequenced with an ABI Prism 310 DNA sequencer (Applied Biosystem) using the amplification primers and two internal primers. SM and SNP were identified and numerated by comparison with the published germline sequence of the first BCL6 intron (AF 191831). All mutations retained for the analysis were confirmed by a second PCR procedure.
BCL6 protein expression by immunohistochemical analysis BCL6 protein was detected with monoclonal antibody (clone PG.B6p, 1 : 40 dilution, Dako, Glostrup, Denmark). Immunostaining techniques were performed in paraffin-embedded tissues sections. Only nuclear BCL6 staining was considered for positivity and was assessed semiquantitatively by two of the authors (JMP, FJ). Percentages of neoplastic cells were assigned to one of the following categories: less than 25, 25-50%, 50-75%, and 475%. BCL6 positive reactive lymphocytes were used as internal control.
BCL6 gene expression
The mRNA BCL6 gene expression was assessed by a real-time quantitative RT-PCR assay in 18 available tumor samples as previously described 11 and was correlated to the mutational status. The housekeeping PBGD gene was used as internal control.
Gel mobility-shift assay
A gel mobility-shift assay using a double-stranded DNA probes containing a sequence encompassing one of the two SNPs located at position 397 and 520 was performed.
The probes G397C and DT520 were defined as follows: CCCCAGACCGC G/C GAGAGGACG and CTTTCCTTGC T/-CCGTCGCTCC, respectively. Nuclear extracts were prepared by the method of Schreiber et al 22 and were obtained from 2 t(14;18) þ higher grade transformed FL cell lines (DHL16, RL4). 23, 24 Binding reactions were performed in a total volume of 10 ml containing 2 ml of extract, 2 ml of 5 Â binding buffer (20% glycerol, 5 mM MgCl 2 , 2.5 mM EDTA, 2.5 mM DTT, 250 mM NaCl, 50 mM Tris-HCl (pH 7.5) and 0.25 mg/ml poly(dI-dC)/ poly(dI-dC); Promega, Madison, WI) and 1 ml of double stranded, 32 P-end labeled probes. Incubations were carried out for 20 min at 201C and the resulting complexes were resolved on 4% nondenaturating polyacrylamide gels in 0.5 Â Tris-Borate EDTA. For competition experiments, incubations were performed with a 100-fold-excess of unlabeled probe.
Statistical analysis
Genotype frequency comparisons, correlation with BCL6 SM, SNPs, clinical characteristics, and BCL6 protein expression were Inherited and acquired mutations of the BCL6 first intron in follicular lymphoma F Jardin et al analyzed using the Fisher's exact test. To avoid report of chance correlations, adjustment for multiple testing was performed using the Bonferroni correction, giving a significant P-value o0.003. Relative risks associated with a particular genotype were estimated by the odd ratio (OR) formula and were given within a 95% confidence interval (CI). OS duration was measured from the time of diagnosis to the date of death or last follow-up alive. Progression-free survival (PFS) was calculated from the initiation of the treatment to the date of relapse, progression or death from any cause. The cumulative proportion of patients, which undergo transformation in DLBCL, was calculated from the time of diagnosis to the date of transformation. Only histological confirmed transformations were retained for the study. The PFS and the OS were estimated by the KaplanMeier method and statistical differences were assessed by the log-rank test (P-value o0.05). BCL6 mRNA expression between mutated and unmutated cases was compared using the Mann and Whitney test. All statistical analyses were performed using Statview s software.
Results
Frequency of the G397C, G502A, and DT520 alleles in the t(14;18) FL population, in 3q27 þ NHL and in controls
The distribution of the three BCL6 SNPs in 97 t(14;18) FL and in the control population is shown in Table 2 . Allelic frequencies did not differ between both studied population, demonstrating that these polymorphisms are not associated with an increased susceptibility to FL in a French population based study. Analysis performed on 55 matched DNA from PBMCs confirmed the constitutional nature of the G397C and G502A SNPs. Furthermore, by contrast to previous reports, 20, 25 we confirmed the constitutional origin of the T deletion located on nucleotide 520. In addition, we observed in 4/97 cases an SNP, defined by a T nucleotide addition at position 756, which has not been previously reported. The control group and the t(14;18) FL group were both in a Hardy-Weinberg equilibrium for the (397C, 397G) and (520T, 520DT) alleles. The 502A variant allele was constantly linked to the 520DT variant (P ¼ 0.0003).
The distribution of the three BCL6 SNPs in 54 NHL with 3q27 rearrangement and the control population was similar. SNPs frequencies between the t(14;18) þ FL group and the t(3;y) NHL group were compared. A significant higher frequency of the 520DT genotype was observed in the t(3;y) NHL group (21/54 cases, 38.9%) (OR ¼ 2.79, CI, 1.32-5.9, P ¼ 0.02). However, this difference was not significant when compared to the control group (Table 2) .
Correlation between BCL6 SNPs and clinical features in FL
After adjustment for multiple testing, we did not observe any significant correlation between performance status, IPI score, LDH level, presence of a bulky disease, extranodal involvement, bone marrow involvement, and the 397/520 genotypes.
No significant correlation between the OS or PFS and the different genotypes was demonstrated. However, the time to transformation was significantly shorter in the 397G/C genotype group as compared to the 397G/G genotype group (P ¼ 0.02) (Figure 1) . Similar results were observed in the subgroup of patients treated in first-line by an anthracyclin-based regimen (P ¼ 0.04). At 5 years, the cumulative rate of transformation was Table 2 Distribution of three single-nucleotide polymorphisms of the first BCL6 intron and allele frequencies in follicular lymphoma cases, control population, and lymphomas with 3q27 rearrangement Inherited and acquired mutations of the BCL6 first intron in follicular lymphoma F Jardin et al 18% (CI 13-23%) in the 397G/C genotype group and 40% (CI 28-52%) in the 397G/C subgroup. This difference was most likely unrelated to the BCL6 translocation status, because a similar frequency of 3q27 rearrangements was observed in the 397G/C and 397G/G subgroups (15 and 19%, respectively We did not demonstrate any correlation between BCL6 protein expression and the genotype distribution. The SM status (mutated/unmutated) was similar in patients with a high BCL6 protein expression (475%) as compared to patients with a low BCL6 protein expression (less than 75%). FL cases with SM targeting hot spots were equally distributed in groups with a high or low BCL6 expression (data not shown). Single-nucleotide polymorphisms are not indicated. Nucleotide numbering is assigned according to the previously published sequence (AF191831). Mutations occurring at a previously reported hot-spot (clusters 106-127 and 423-443) are underlined. Recurrently mutated positions are indicated (in italic).
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Gel mobility-shift assay
Gel-shift assays were carried out in order to assess the existence of transcription factor binding sites, which may potentially be modified by the SNPs. Electrophoresis mobility shift assay using DNA probes encompassing the 397G/C or 520T/DT SNPs shows representative results for protein/DNA complexes ( Figure 3 ). Specificity was demonstrated by competition experiments with the unlabeled oligonucleotide in both cases. The nucleotide at position 397 (G or C) did not create a putative protein binding site as we failed to show any difference between the two probes.
Competitions experiments were performed with the 397G probe (G) and the 397C probe (C), showing a more effective binding inhibition with the 397C unlabeled probe, suggesting that the SNP located at position 397 may influence protein affinity of a putative transcriptional factor (Figure 3a) . By contrast, the deletion of T at position 520 was clearly related to a specific band shift pattern as compared to the þ T520 probe, suggesting that the SNP at position 520 may have a functional impact by modifying DNA/protein interaction ( Figure 3b ) and/or generating a new binding site.
Discussion
SNP changes occurring in the coding regions and/or in the regulatory regions of the genes may affect function or expression of their proteins products. In NHL, SNPs of several genes have been previously related to lymphoma susceptibility, such as genes coding for xenobiotic proteins (GSTT1, PON1, Methionine synthase), 26, 27 inflammation regulator cytokines (IL1, IL10, TNFa), [28] [29] [30] mismatch repairing elements (hMSH2), 31 or oncoproteins (H-ras 1). 32 Since BCL6 plays a crucial role during both normal B-cell maturation and lymphomagenesis, it has been hypothesized that constitutional or acquired mutations of putative functional elements may impact on lymphoma predisposition or lymphoma outcome. In a casecontrol study, using a PCR-RFLP method, Lossos et al 21 reported that the 397C allele was associated with an increased susceptibility to develop FL. By contrast, we could not extend this observation in a French   10  20  30  40  50  60  70  80  90  100  110  120  130  140  150  160  170  180  190  200  210  220  230  240  250  260  270  280  290  300  310  320  330  340  350  360  370  380  390  400  410  420  430  440  450  460  470  480  490  500  510  520  530  540  550  560  570  580  590  600  610  620  630  640  650  660  670  680  690  700  710  720  730  740  750  760  770  780 
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Figure 2
Distribution of 79 mutations occurring in 38 follicular lymphoma cases along the major mutation cluster. Single-nucleotide polymorphisms are not indicated.
Probe 397G Probe 520∆T Probe 520T Figure 3 Gel mobility-shift assay using double-stranded DNA probes showing the presence of DNA/protein complexes. DNA probes encompassing one of the two SNP located at position 397 and 520 were used. Nuclear extracts were obtained from two lymphoma cell lines (DHL16, RL4) harboring a t(14;18) translocation. Binding was competed by the addition of 100-fold excess amounts of unlabeled probe (competitor þ or À). Arrows indicate the DNA/protein complexes. (a) Competitions experiments were performed with the 397G (g) and the 397C (c) probes, showing a more effective competition by the 397C unlabeled probe. (b) An additional DNA/ protein complex (gray arrow) was observed with the 520DT probe as compared to the 520T.
Inherited and acquired mutations of the BCL6 first intron in follicular lymphoma F Jardin et al population of FL and failed to demonstrate any correlation between three SNPs located within the MMC, including the 397G/C SNP, and susceptibility to FL. We observed a strictly similar frequency of the 397C allele (0.11) between the 98 American control subjects, the 106 French based population controls, and the 97 FL subjects. 21 These results suggest that, despite their morphological similarities, FLs emerging in different geographic areas may occur in a different inherited genetic susceptibility background. 33 The 502A/520DT genotype is more prevalent in the 3q27 þ NHL group than in the control group, suggesting a possible relation between these SNPs and the BCL6 translocation. However, due to the very low frequency of the 502A/520DT genotype, the trend observed in our study warrants confirmation in a larger population. It is of note that these SNPs are included in the hyper-cluster region as defined by Akasaka et al. 9 This region contains most of the breakpoints involving BCL6 translocations and is frequently targeted by the SM process. 9, 34, 35 We demonstrated using a band-shift assay that the deletion of T nucleotide at position 520 generates a protein binding site, suggesting that a factor binding this region could be involved in the translocation mechanism.
SNPs have been shown to influence clinical outcome in NHL. For instance, genetic polymorphisms leading to an increase level of TNFa contribute significantly to a higher rate of relapse and progression in DLBCL. 36 We show that the 397G/C genotype may be associated to an increase risk of higher-grade transformation. The specific role of BCL6 in the higher-grade transformation of FL has been previously suggested. 37 In some cases, SM occurring during the transformation process are likely to increase BCL6 mRNA expression by disrupting negative regulatory elements. 38, 39 On the other hand, histological transformation of FL to higher grade can be associated with a reduced expression of the BCL6 protein, despite the presence of additional SM, indicating that BCL6 upregulation is not uniformly required for transformation. 39 As previously reported, 21 we failed to show any correlation between BCL6 expression and the 397 SNP, suggesting an indirect effect of the 397C SNP by a linkage desequilbrium with another gene located on the same chromosome. For instance, such phenomenon could explain the relation between a BCL6 SNP and the increase susceptibility to breast cancer. 40 Our study suggests that in a neoplastic setting, a polymorphism of BCL6 may lead to a higher risk for transformation, eventually by facilitating indirectly oncogenes activation. A study of a larger population is required to confirm this observation.
The clinical signification and prognosis value of BCL6 SM in NHL is still unclear. Vitolo et al 15 have shown that DLBCL with BCL6 SM treated by standard chemotherapy had a significantly improved 5-year disease-free survival as compared to unmutated patients. However, surprisingly, the presence of SM was correlated to unfavorable well-known clinical factors such as elevated LDH level, bulky disease, and a high IPI score. In a distinct series of 45 DLBCL, the presence of SM in the 423 to 443 cluster was correlated to an increased OS as compared to the unmutated cases. 16 We confirmed a clustering effect of the distribution of mutations along the MMC but failed to show any favorable prognosis impact on FL. As BCL6 protein is constantly expressed in FL, but only in B40% of DLBCL, 3 it is not surprising that the clinical relevance of the BCL6 mutational status, despite similar molecular characteristics, differs between the two NHL subtypes. For instance, SM may reflect a normal mutational process with no impact on the BCL6 constitutional expression in FL. By contrast, BCL6 SM in DLBCL may be related to the phenotype (ie GC B-cell like or activated B-cell like phenotypes) or may result of an aberrant SM process targeting several genes involved in lymphomagenesis. 41 Recently, it has been shown in early stage B-cell chronic lymphocytic leukemia that the coexistence of IgV and BCL6 mutations correlated with shorter treatment free interval, as compared to cases harboring only IgV mutations. 17 These observations indicate that the BCL6 SM clinical value is highly dependent of the maturation stage of the lymphoma cell in which the SM process occurs.
To conclude, our study demonstrates that the first BCL6 intron is a highly variable region as a consequence of both inherited and acquired mutations, contributing to the biology and outcome of FL. Whether these genetic changes act directly on the tumor behavior or may represent an indirect involvement of unknown genes is still an unresolved question.
